FOXA1 in Prostate Cancer

Overview

Journal Asian J Androl

Specialty Urology

Date 2022 Aug 26

PMID 36018068

Authors

Hui-Yu Dong

Lei Ding

Tian-Ren Zhou

Tao Yan

Jie Li

Chao Liang

Affiliations

Soon will be listed here.

Abstract

Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional network shifted. Forkhead box protein A1 (FOXA1) may play a key role in this process through multiple mechanisms. To better understand the role of FOXA1 in prostate cancer, we review the interplay among FOXA1-targeted genes, modulators of FOXA1, and FOXA1 with a particular emphasis on androgen receptor (AR) function. Furthermore, we discuss the distinct role of FOXA1 mutations in prostate cancer and clinical significance of FOXA1. We summarize possible regulation pathways of FOXA1 in different stages of prostate cancer. We focus on links between FOXA1 and AR, which may play different roles in various types of prostate cancer. Finally, we discuss FOXA1 mutation and its clinical significance in prostate cancer. FOXA1 regulates the development of prostate cancer through various pathways, and it could be a biomarker for mCRPC and NEPC. Future efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate cancer. We believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer.

Citing Articles

Human immune system: Exploring diversity across individuals and populations.

Hoang Nguyen K, Le N, Nguyen P, Nguyen H, Hoang D, Huynh C Heliyon. 2025; 11(2):e41836.

PMID: 39911431 PMC: 11795082. DOI: 10.1016/j.heliyon.2025.e41836.

Phase Separation Mediated Sub-Nuclear Compartmentalization of Androgen Receptors.

Yavuz S, Abraham T, Houtsmuller A, van Royen M Cells. 2024; 13(20.

PMID: 39451211 PMC: 11506798. DOI: 10.3390/cells13201693.

In Silico Analysis Uncovers FOXA1 as a Potential Biomarker for Predicting Neoadjuvant Chemotherapy Response in Fine-Needle Aspiration Biopsies.

Yin Z, Tao J, Liu Y, Chen H, Hu K, Wang Y J Cancer. 2024; 15(18):6052-6072.

PMID: 39440050 PMC: 11493000. DOI: 10.7150/jca.101901.

DARDN: A Deep-Learning Approach for CTCF Binding Sequence Classification and Oncogenic Regulatory Feature Discovery.

Cho H, Wang Z, Cong Y, Bekiranov S, Zhang A, Zang C Genes (Basel). 2024; 15(2).

PMID: 38397134 PMC: 10888155. DOI: 10.3390/genes15020144.

Presenilin-1-Derived Circular RNAs: Neglected Epigenetic Regulators with Various Functions in Alzheimer's Disease.

Sanadgol N, Amini J, Beyer C, Zendedel A Biomolecules. 2023; 13(9).

PMID: 37759801 PMC: 10527059. DOI: 10.3390/biom13091401.

References

Lee H, Hwang M, Chattopadhyay S, Choi H, Lee K . Hepatocyte nuclear factor-3 alpha (HNF-3alpha) negatively regulates androgen receptor transactivation in prostate cancer cells. Biochem Biophys Res Commun. 2008; 367(2):481-6. DOI: 10.1016/j.bbrc.2007.12.162. View

Pomerantz M, Li F, Takeda D, Lenci R, Chonkar A, Chabot M . The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015; 47(11):1346-51. PMC: 4707683. DOI: 10.1038/ng.3419. View

Chenoweth D, Dervan P . Allosteric modulation of DNA by small molecules. Proc Natl Acad Sci U S A. 2009; 106(32):13175-9. PMC: 2726366. DOI: 10.1073/pnas.0906532106. View

Daskivich T, Chamie K, Kwan L, Labo J, Palvolgyi R, Dash A . Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117(10):2058-66. DOI: 10.1002/cncr.25751. View

Knudsen K, Penning T . Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab. 2010; 21(5):315-24. PMC: 2862880. DOI: 10.1016/j.tem.2010.01.002. View

Fernandes R, Toubia J, Townley S, Hanson A, Dredge B, Pillman K . Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Rep. 2021; 34(1):108585. DOI: 10.1016/j.celrep.2020.108585. View

Attard G, Parker C, Eeles R, Schroder F, Tomlins S, Tannock I . Prostate cancer. Lancet. 2015; 387(10013):70-82. DOI: 10.1016/S0140-6736(14)61947-4. View

Qi J, Nakayama K, Cardiff R, Borowsky A, Kaul K, Williams R . Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell. 2010; 18(1):23-38. PMC: 2919332. DOI: 10.1016/j.ccr.2010.05.024. View

Malik S, Jiang S, Garee J, Verdin E, Lee A, OMalley B . Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol. 2009; 30(2):399-412. PMC: 2798473. DOI: 10.1128/MCB.00907-09. View

10.

Vandekerkhove G, Todenhofer T, Annala M, Struss W, Wong A, Beja K . Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017; 23(21):6487-6497. DOI: 10.1158/1078-0432.CCR-17-1140. View

11.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

12.

Aggarwal R, Feng F, Small E . Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017; 31(6):467-74. View

13.

Wang L, Xu M, Kao C, Tsai S, Tsai M . Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. J Clin Invest. 2019; 130(4):1782-1792. PMC: 7108891. DOI: 10.1172/JCI126327. View

14.

Mansor R, Holly J, Barker R, Biernacka K, Zielinska H, Koupparis A . IGF-1 and hyperglycaemia-induced FOXA1 and IGFBP-2 affect epithelial to mesenchymal transition in prostate epithelial cells. Oncotarget. 2020; 11(26):2543-2559. PMC: 7335671. DOI: 10.18632/oncotarget.27650. View

15.

Ratta R, Guida A, Scotte F, Neuzillet Y, Teillet A, Lebret T . PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2020; 23(4):549-560. DOI: 10.1038/s41391-020-0233-3. View

16.

Hernandez-Llodra S, Segales L, Safont A, Juanpere N, Lorenzo M, Fumado L . SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer. Prostate. 2019; 79(10):1156-1165. DOI: 10.1002/pros.23830. View

17.

Jia L, Berman B, Jariwala U, Yan X, Cogan J, Walters A . Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One. 2008; 3(11):e3645. PMC: 2577007. DOI: 10.1371/journal.pone.0003645. View

18.

Cunha G, Donjacour A, Cooke P, Mee S, Bigsby R, Higgins S . The endocrinology and developmental biology of the prostate. Endocr Rev. 1987; 8(3):338-62. DOI: 10.1210/edrv-8-3-338. View

19.

Knudsen K, Scher H . Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009; 15(15):4792-8. PMC: 2842118. DOI: 10.1158/1078-0432.CCR-08-2660. View

20.

Chen Z, Song X, Li Q, Xie L, Guo T, Su T . Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene and lncRNA in Prostate Cancer. Cells. 2019; 8(8). PMC: 6721761. DOI: 10.3390/cells8080864. View